Ingrid A. Mayer, MD, MSCI

Vice President, Global Clinical Strategy Head – Women’s Cancers Vice President, Global Clinical Strategy Head – Women’s Cancers AstraZeneca Late Development Oncology Gaithersburg, Maryland

After 20 years in academia and clinical practice as a breast cancer medical oncologist, Dr. Mayer’s current role at AstraZeneca is to pioneer and expand novel translational global research and innovative clinical trial development in breast cancer that accelerates the approval of established and novel drugs in the key areas of excellence at AstraZeneca, tumor resistance/ targeted therapies, DNA damage response, antibody-drug conjugates, and immuno-oncology. Before joining AZ, Dr. Mayer was a Professor of Medicine and Ingram Professor of Cancer Research at Vanderbilt University Medical Center with a successful track record of phase I, II and III clinical trials and has chaired, co-chaired or been a member of many national and international health services cancer leadership committees in the US, such as ECOG-ACRIN Breast Core Committee, National Comprehensive Cancer Network (NCCN) Breast Cancer Panel of Experts, Translational Breast Cancer Research Consortium (TBCRC) amongst many others. Her translational research focused on identifying targetable pathways and mechanisms of treatment resistance in breast cancer, which have been recognized and funded by the NCI (K23 and SPORE in Breast Cancer), SU2C/ AACR, Susan G. Komen Foundation and the Breast Cancer Research Foundation and published in more than 130 peer-reviewed journals.

    Your Cart
    Your cart is emptyReturn to Shop